<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904612/" ref="ordinalpos=1595&amp;ncbi_uid=5782633&amp;link_uid=PMC3904612" image-link="/pmc/articles/PMC3904612/figure/F8/" class="imagepopup">Figure 8. Model of MNK1-mediated resistance to rapalogs..  From: MNK1 <span class="highlight" style="background-color:">pathway</span> activity maintains protein synthesis in rapalog-treated gliomas. </a></div><br /><div class="p4l_captionBody">Rapalogs abrogate mTORC1-mediated inhibition of 4EBP1 phosphorylation at Ser65 and Thr70. Activated by rapalogs, the MNK1 signaling pathway phosphorylates eIF4E and maintains 4EBP1 phosphorylation at Ser65. Activation of the MNK1/eIF4E pathway increases translation of cancer-promoting and antiapoptotic proteins, whereas 4EBP1 phosphorylation followed by eIF4E dissociation allows continued protein synthesis and, thus, cancer cell survival.</div></div>